Pharmaceuticals & Biotech U.S. Community
Our community narratives are driven by numbers and valuation.
Pharmaceuticals & Biotech U.S. Investing Ideas
Unicycive Therapeutics (Nasdaq: UNCY) – Preparing for a Second Shot at Bringing a New Kidney Treatment to Market (TEST)
Key Takeaways Unicycive has completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC is designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability for dialysis patients with hyperphosphatemia.Read more
The "Molecular Pencil": Why Beam's Technology is Built to Win
The "Molecular Pencil": Why Beam's Technology is Built to Win The investment thesis in Beam Therapeutics is a long-term, high-conviction bet on a fundamental technological shift in genetic medicine. While first-generation gene editors like CRISPR-Cas9 function as "molecular scissors," they are an inherently disruptive tool.Read more
PRME remains a long shot but publication in the New England Journal of Medicine helps.
PRME Medicine has just announced the publication of an important article in The New England Journal of Medicine. The article announces success in developing a new treatment using gene editing and stem cell therapy in clinical trials.Read more
Eli Lilly's Future Growth Driven by Tirzepatide and Favorable Market Conditions
Catalysts Mounjaro/Zepbound: Lilly’s tirzepatide franchise is the engine of growth. Mounjaro (for type 2 diabetes) and Zepbound (obesity) each grew rapidly in 2024.Read more
Dead in the water.
Firstly, this is purely to remove the stock from mine and everybody else's radar as Simply is showing this as an undervalued company which is essentially dead in the water and not currently tradeable on the exchange. The following is AI, not my own words, which has a far more explanatory way of putting this.Read more
Very Bullish
It is almost impossible to obtain a drug label from the FDA for pediatric use - this topical non-steroidal drug ZORYVE is very safe and highly effective for both pediatric and adult patients. The drug is potent in the skin, it is not well absorbed and is quickly metabolized which limits systemic exposure and minimizes side effect risks.Read more
Very Bullish
98% of pancreatic cancer patients in Phase II study generated powerful immune responses to the KRAS antigens. Median T-cell immune response above threshold was 44-fold.Read more
LENZ Therapeutics - a high risk high reward small cap biotech stock
Hello Simply Wallstreet I have some DD on a small cap company I want to share. Firstly I want you all to be aware of the risks associated with small caps.Read more
Alzamend Neuro's Novel Lithium Formulation Will Target Major Mental Health Challenges
Catalysts AL001 : a novel lithium formulation targeting Alzheimer's disease, Bipolar Disorder, Major Depressive Disorder (MDD), and PTSD. Phase II studies show promising safety/efficacy, with trials ongoing as of 2025.Read more
